Dr. Wood-Horrall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Highway 71 E
Smithville, TX 78957Phone+1 512-237-5736Fax+1 512-237-5704
Education & Training
CHRISTUS Health/Texas A&M University School of MedicineResidency, Emergency Medicine, 2010 - 2013
University of Texas Medical Branch School of MedicineClass of 2010
Certifications & Licensure
TX State Medical License 2013 - 2025
Clinical Trials
- Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin Start of enrollment: 2015 Dec 01
Publications & Presentations
PubMed
- 30 citationsA randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.Francisco J. Esteva, Justin Stebbing, Rebecca N. Wood-Horrall, Peter J. Winkle, Sung Young Lee
Cancer Chemotherapy and Pharmacology. 2018-01-12 - 25 citationsThe Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin ☆Susan K. Paulson, Rebecca N. Wood-Horrall, Randall Hoover, Megan Quintas, Laura Lawrence
Clinical Therapeutics. 2017-06-01 - 9 citationsImpact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.Ken Ogasawara, Rebecca N. Wood-Horrall, Mark Thomas, Michael Thomas, Liangang Liu
Cancer Chemotherapy and Pharmacology. 2021-09-03
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
